Influenza A/Singapore (H3N2) component vaccine in systemic lupus erythematosus: A distinct pattern of immunogenicity

CONCLUSION: Influenza A/Singapore (H3N2) vaccine has an adequate safety profile. The distinct immunogenicity pattern from other influenza A components characterized by a remarkably high pre- and post-vaccination SP rate and high GMT levels may be associated with previous influenza A vaccination. (www.clinicaltrials.gov, NCT03540823).PMID:34459317 | DOI:10.1177/09612033211040371

Source: Lupus - August 30, 2021 Category: Rheumatology Authors: Francisco Fellipe Claudino Formiga Clovis Artur Silva Tatiana do Nascimento Pedrosa Nadia Emi Aikawa Sandra Gofinet Pasoto Cristiana Couto Garcia Artur Silva Vidal Cap ão Victor Adriano de Oliveira Martins Adriana Coracini Tonacio de Proen ça Ricardo Fu Source Type: research